<DOC>
	<DOCNO>NCT01429194</DOCNO>
	<brief_summary>The Articulating Circular Endoscopic ( ACE ) Stapler investigational system use endoscopic guidance trans-orally place plication stomach obese subject reduce volume expansion fundus great curve abate hunger part supervise weight reduction program . The primary objective study perform evaluation safety plication procedure . The secondary objective study evaluate preliminary efficacy ACE Stapler treatment obesity 24 month follow-up period .</brief_summary>
	<brief_title>The ACE Follow-up Study</brief_title>
	<detailed_description>This study originally sponsor BaroSense , Inc ( protocol 11-03 ) . 69 subject enrol treated part study 6 center 4 country outside United States . On April 30 , 2013 BaroSense Inc go business study terminate participate center ' Ethics Committees . At point study termination , patient middle post procedure follow-up . Boston Scientific since acquire technology study re-initiate follow-up 24 month order collect data support original safety efficacy endpoint protocol . Only 69 subject previously enrol treated BaroSense 's protocol 11-03 eligible participation Boston Scientific continue follow-up study ( `` The ACE Follow-up Study '' protocol 90891629 ) . The Boston Scientific protocol approve participate center ' Ethics Committees patient choose participate The ACE Follow-up Study need sign new , Ethics Committee Approved , inform consent form .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<criteria>1 . Subject , male female , age 18 50 year age . 2 . Subject must able understand willing sign inform consent document . 3 . Subject must willing able participate aspect study agree comply study requirement duration study . This include availability reliable transportation sufficient time attend followup visit . 4 . Subject BMI 40 45 30 39.9 plus one comorbid diseases expect improve weight loss , include limited hypertension , dyslipidemia , obstructive sleep apnea , diabetes mellitus . 5 . Subject must fully ambulatory , without chronic reliance walk aid crutch , walker wheelchair . 6 . Subject must sufficient stable medical health , evaluate Principal Investigator . 7 . Subject must primary care physician manage subject comorbid condition throughout study . 8 . Subject must fail standard obesity therapy diet , exercise , behavior modification , pharmacologic agent either alone combination , assessed interview member study team baseline . 9 . Subject agree refrain type reconstructive surgery may affect body weight mammoplasty abdominal lipoplasty liposuction , trial . 1 . Subject history of/or sign and/or symptom gastroduodenal ulcer disease . 2 . Subject poorly control diabetes indicate lack stable diabetes medication dos last month , history diabetes great 10 year . 3 . Subject significant weight loss last 3 month , baseline study procedure . 4 . Subject history diagnose eat disorder . 5 . Subject history peptic ulcer test positive H. pylorus , unless treat procedure . 6 . Subject symptomatic congestive heart failure , cardiac arrhythmia unstable coronary artery disease . 7 . Subject preexist respiratory disease chronic obstructive pulmonary disease ( COPD ) , pneumonia cancer . 8 . Subject significant esophageal disease include Zenker 's diverticulum , grade 34 reflux esophagitis , stricture , Barrett 's esophagus , esophageal cancer , esophageal diverticulum , dysphagia , achalasia , symptoms dysmotility . 9 . Subject observe EGD heavily scar , malignant poor quality/friable tissue area stomach plication place .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Weight Loss</keyword>
	<keyword>Trans-oral Endoscopic Procedure</keyword>
	<keyword>Gastric Plication</keyword>
</DOC>